| Literature DB >> 32139762 |
B M Antunes1, F E Rossi2, L M Oyama3, J C Rosa-Neto4, F S Lira2.
Abstract
Physical inactivity has emerged as an important cardiometabolic risk factor; however, the beneficial impacts of physical exercise according physical fitness status are still unclear. To analyze the lipoproteins and immune-endocrine response to acute aerobic exercise sessions performed at different intensities according physical fitness status and evaluated the gene expression in monocyte cells. Twelve individuals, divided into Low and High VO2max, performed three randomized acute exercise sessions at low (<60% VO2max), moderate (60-75% VO2max), and high (>90% VO2max) intensities. Blood samples were collected pre, immediately post, and 60 minutes post-exercise to analyze NEFA, triacylglycerol, non-HDL-c, HDL-c, PAI-1, leptin and adiponectin concentrations. Blood samples were collected from another set of twelve individuals for use in monocyte cell cultures to analyze L-CAT, CETP, and AMPK gene expressions. Low VO2max group pre-exercise exhibited higher postprandial leptin and total cholesterol concentrations than High VO2max group (p < 0.05). Exercise performed in high-intensity promoted a decreased leptin and NEFA levels (p < 0.05, for both), but for PAI-1 levels was decreased (p < 0.05) only for the Low VO2max group. Triacylglycerol levels decreased after all exercise sessions (p < 0.05) for both groups, and HDL-c exhibited decrease during moderate-intensity (p < 0.05), but this scenario was attenuated in Low VO2max group. Low VO2max individuals exhibit some metabolic-endocrine disruption, and acute aerobic exercise sessions performed at low, moderate, and high intensities are capable of modulating metabolic-endocrine parameters, mainly at high-intensity, in a physical fitness-dependent way, given that Low VO2max group was more responsive and seem to be able to appropriate more exercise-related benefits.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32139762 PMCID: PMC7058045 DOI: 10.1038/s41598-020-61039-6
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Sequences of forward and reverse primers used for RT-PCR.
| Gene | Primer Forward | Primer Reverse |
|---|---|---|
| ACAACTTTGGTATCGTGGAAGG | GCCATCACGCCACAGTTTC | |
| AAGCTGGACAAACCAGATGTG | TAGACAACCCTGGTGTTATCG | |
| AAATCTTCCAAGAGGTTGTCGG | CCATCACTGAAGAATTGACCAC | |
| GGCACGCATACCCTTGAT | TCTTCCTTCGTACACGCAAATAA |
GAPDH = Glyceraldehyde 3‐phosphate dehydrogenase gene; L-CAT = Lecithin-cholesterol acyltransferase; CETP = Cholesteryl ester transfer protein; AMPK = AMP-activated protein kinase.
Performance, inflammatory and metabolic parameters according physical fitness status (Low and High VO2max).
| Fitness | Low VO2max (n=6) | High VO2max (n=6) | p-value |
|---|---|---|---|
| VO2max (ml.kg.min−1) | 41.0 ± 4.2 | 62.8 ± 4.9 | <0.001 |
| Maximal Workload (watts) | 167.0 ± 33.8 | 263.4 ± 28.2 | <0.001 |
| Leptin (ng.mL1) | 8.5 ± 5.4 | 2.7 ± 3.0 | 0.045 |
| Adiponectin (μg.mL−1) | 11.2 ± 3.4 | 12.1 ± 8.0 | 0.817 |
| PAI-1 (ng.mL−1) | 20.9 ± 16.7 | 23.6 ± 23.9 | 0.822 |
| NEFA (mEq.L) | 0.89 ± 0.02 | 0.91 ± 0.03 | 0.369 |
| TAG (mg.dL−1) | 128.6 ± 28.7 | 150.5 ± 31.7 | 0.239 |
| TC (mg.dL−1) | 192.8 ± 24.2 | 163.3 ± 17.3 | 0.035 |
| LDL-c (mg.dL−1) | 122.9 ± 25.0 | 96.5 ± 16.8 | 0.057 |
| HDL-c (mg.dL−1) | 44.1 ± 8.8 | 36.6 ± 4.2 | 0.091 |
| Non-HDL (mg.dL−1) | 148.7 ± 27.2 | 126.6 ± 14.7 | 0.111 |
PAI-1 = plasminogen inhibitor-1; NEFA = Non-esterified fatty acids; TAG = triacylglycerol; TC = total cholesterol; LDL-c = low density lipoprotein; HDL-c = high density lipoprotein.
Comparison between different intensities on the inflammatory response, according physical fitness status (low and high VO2max).
| Variables | Intensity | Low VO2max | High VO2max | ||||
|---|---|---|---|---|---|---|---|
| Pre | Post | 60 min | Pre | Post | 60 min | ||
| Leptin (ng.mL1) | 8.2 ± 7.6 | 5.9 ± 4.5 | 4.3 ± 2.9# | 1.4 ± 1.0¥ | 1.2 ± 0.9¥ | 2.4 ± 3.2¥,# | |
| 10.7 ± 5.8 | 10.6 ± 6.0 | 8.0 ± 4.2# | 4.0 ± 6.0¥ | 2.6 ± 3.5¥ | 1.4 ± 1.3¥,# | ||
| 6.4 ± 5.2 | 5.5 ± 4.3 | 6.8 ± 5.1# | 2.6 ± 3.0¥ | 2.8 ± 3.6¥ | 2.4 ± 2.8¥,# | ||
| Adiponectin (μg.mL−1) | 10.9 ± 4.9 | 10.3 ± 3.3 | 10.5 ± 7.5 | 14.6 ± 7.5 | 13.9 ± 8.0 | 9.4 ± 4.5 | |
| 12.0 ± 2.7 | 11.4 ± 4.8 | 11.1 ± 5.3 | 12.3 ± 8.7 | 11.5 ± 7.6 | 12.1 ± 9.6 | ||
| 10.7 ± 4.4 | 12.3 ± 7.3 | 12.5 ± 6.1 | 9.3 ± 8.7 | 8.8 ± 3.9 | 8.4 ± 6.1 | ||
| PAI-1 (ng.mL−1) | 20.7 ± 17.4 | 20.8 ± 15.2 | 15.2 ± 11.0b | 26.1 ± 23.7 | 24.0 ± 23.2 | 23.7 ± 23.6 | |
| 18.6 ± 14.2 | 24.1 ± 16.6 | 14.9 ± 13.1b | 25.2 ± 24.5 | 27.1 ± 25.7 | 28.9 ± 22.2 | ||
| 23.3 ± 19.7 | 33.2 ± 19.7 | 21.3 ± 19.6b | 19.6 ± 24.9 | 20.6 ± 25.2 | 23.2 ± 24.7 | ||
| NEFA (mEq.L) | 0.89 ± 0.03 | 0.86 ± 0.04 | 0.90 ± 0.05b | 0.91 ± 0.04 | 0.88 ± 0.06 | 0.98 ± 0.10b | |
| 0.91 ± 0.02 | 0.91 ± 0.04 | 0.92 ± 0.02 | 0.93 ± 0.05 | 0.90 ± 0.08 | 0.89 ± 0.02 | ||
| 0.89 ± 0.05 | 0.84 ± 0.03 | 0.93 ± 0.05 | 0.90 ± 0.02 | 0.85 ± 0.0a | 0.94 ± 0.03b | ||
PAI-1 = plasminogen activator inhibitor-1; NEFA = Non-esterified fatty acids; aBonferroni’s post hoc with p < 0.05 compared to rest; bBonferroni’s post hoc with p < 0.05 compared to post-exercise; #main effect of time with significant difference from Post; £significant difference between moderate-intensity; ¥significant difference between group (High vs low VO2max).
Figure 1Leptin modulation before exercise sessions performed at low, moderate and high intensities according physical fitness status. #Main effect of time with significant difference from Post; £significant difference between moderate-intensity; ¥significant difference between group (High vs Low VO2max).
Comparison between different intensities, according physical fitness status (low and high VO2max) in the lipid profile.
| Variables | Intensity | Low VO2max | High VO2max | ||||
|---|---|---|---|---|---|---|---|
| Pre | Post | 60 min | Pre | Post | 60 min | ||
| TAG (mg.dL−1) | 123.2 ± 30.1 | 111.9 ± 23.9* | 116.3 ± 25.6* | 151.1 ± 35.1 | 134.3 ± 30.1* | 124.9 ± 15.7* | |
| 122.5 ± 16.1 | 114.3 ± 9.9* | 109.0 ± 4.8* | 151.1 ± 41.3 | 118.6 ± 21.3* | 112.3 ± 6.5* | ||
| 140.1 ± 52.9 | 131.9 ± 39.5* | 133.1 ± 37.6* | 149.3 ± 29.9 | 141.5 ± 26.7* | 132.9 ± 14.3* | ||
| TC (mg.dL−1) | 186.8 ± 27.1 | 181.7 ± 27.7 | 180.6 ± 37.5 | 166.5 ± 23.4 | 184.4 ± 34.6 | 182.8 ±± 31.7 | |
| 194.4 ± 31.2 | 177.1 ± 25.3 | 170.2 ± 20.0 | 151.7 ± 11.9 | 160.7 ± 17.2 | 155.5 ± 14.8 | ||
| 197.2 ± 31.3 | 186.9 ± 34.0 | 190.8 ± 29.7 | 171.7 ± 20.7 | 166.6 ± 15.6 | 172.6 ± 14.3 | ||
| LDL-c (mg.dL−1) | 118.7 ±± 27.4 | 117.0 ± 26.6 | 112.2 ± 35.1 | 98.6 ± 20.7 | 121.6 ± 30.0 | 118.2 ± 28.1 | |
| 123.6 ± 36.0 | 107.4 ± 25.7 | 100.0 ± 22.9 | 86.6 ± 14.0 | 101.5 ± 14.6 | 96.5 ± 18.0 | ||
| 126.7 ± 26.7 | 119.0 ± 36.2 | 122.1 ± 36.9 | 104.4 ± 19.0 | 101.9 ± 13.1 | 106.2 ± 13.9 | ||
| HDL-c (mg.dL−1) | 43.4 ± 11.0 | 42.3 ± 9.5 | 45.2 ± 10.0 | 37.7 ± 5.9 | 36.0 ± 5.4 | 39.6 ± 9.3 | |
| 46.4 ± 7.3 | 46.8 ± 7.9 | 48.3 ± 6.6 | 34.8 ± 3.3¥ | 35.4 ± 4.0¥ | 36.5 ± 4.6¥ | ||
| 42.5 ± 10.8 | 41.6 ± 10.3 | 42.1 ± 15.1 | 37.4 ± 4.6 | 36.4 ± 3.0 | 39.8 ± 4.2 | ||
| Non-HDL (mg.dL−1) | 143.3 ± 28.5 | 139.3 ± 25.3 | 135.4 ± 35.7 | 128.8 ± 20.3 | 148.5 ± 33.9 | 143.2 ± 29.7 | |
| 148.1 ± 35.5 | 130.3 ± 26.5 | 121.8 ± 22.2 | 116.8 ± 11.4 | 125.2 ± 18.3 | 119.0 ± 18.9 | ||
| 154.7 ± 34.2 | 145.4 ± 33.5 | 148.7 ± 38.4 | 134.3 ± 17.2 | 130.2 ± 16.8 | 132.8 ± 16.0 | ||
TAG = triacylglycerol; TC = total cholesterol; LDL-c = low density lipoprotein; HDL-c = high density lipoprotein. *Main effect of time with significant difference from rest; ¥significant difference between group (High vs low VO2max).
Figure 2Comparison of the relative gene expression, according to control and Rosiglitazone treatment in the low and high VO2max groups.